51 minutes |
2 days ago
S2 E2 — How COVID-19 is changing patient management and clinical trials
23 minutes |
6 days ago
S2 E1.3 - Challenges and Big Ideas for NAFLD/NASH Patient Diagnosis and Treatment in the Post-Second Wave World
22 minutes |
6 days ago
S2 E1.2 Successfully Managing Clinical Trials during COVID-19's Second Wave
23 minutes |
7 days ago
1.1 - How Recent COVID-19 News Affects NAFLD and NASH Patients
70 minutes |
9 days ago
How Will COVID-19 Affect the Fatty Liver Community in 2021?
24 minutes |
14 days ago
44.4 2020 Year In Review: How Patients and Patient Advocates reacted to a year of lows and high
18 minutes |
14 days ago
44.3 2020 Year In Review: Revisiting the "MAFLD vs. NAFLD" debate
22 minutes |
14 days ago
44.2 2020 Year In Review: Fatty Liver Disease Enters the Public Dialogue in Germany
22 minutes |
14 days ago
44.1 2020 Year in Review: Simplifying NASH Diagnostics Saves Money, improves satisfaction
86 minutes |
16 days ago
2020 Year-End NASH Review 2: Patient Treatment and Perspectives
17 minutes |
21 days ago
43.4 2020 Year in Review: The Law of Unintended Consequences Blesses NASH Drug Development
14 minutes |
21 days ago
43.3 2020 Year in Review: Progress in developing clinical endpoints necessary to support drug approvals
23 minutes |
21 days ago
43.2 2020 Year In Review: Emergence of Non-Invasive Tests and Testing Strategies in fatty Liver Disease
23 minutes |
21 days ago
43.1 2020 Year in Review: Advances in Fatty Liver Disease Drugs and Diagnostics
77 minutes |
23 days ago
2020 Year-End NASH Review 1: Drugs and Diagnostics - Ep 43
48 minutes |
a month ago
Policy 2: Credibility, Convergence and the 2021 Global Liver Institute Action Plan - Ep 42
61 minutes |
a month ago
How Did the Liver Do in the US 2020 Elections? (Part One)
48 minutes |
a month ago
Ep 40 - Links between NAFLD and Cardiovascular disease
52 minutes |
2 months ago
COVID CHAOS: The 2nd Wave - Ep 39
58 minutes |
2 months ago
The Day After TLMdX 2020 Wrapping Up with The View from Across the Atlantic - Ep 38